drugset / Trial / NCT04637620
NMDA Modulation in Major Depressive Disorder
Phase 2
Recruiting
90 enrolled
China Medical University Hospital
Ministry of Science and Technology, Taiwan · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
Most of the current antidepressants for major depressive disorder (MDD) are based upon the monoamine hypothesis which cannot fully explain the etiology of depression. NMDA hypofunction has been implicated in the pathophysiology of depression. Therefore, this study will examine the efficacy and safety as well as cognitive function improvement of an NMDA enhancer (NMDAE) in the treatment of MDD in the adults.
Timeline
- Start
- 2017-06-01
- Primary completion
- 2026-11
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Sertraline | Small molecule | — | — |